Terry Phillis, MD
Urology · Anniston, ALNPI 1750359030
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,170 of the $6,720 with a category attached, or 76.9%. It is spread thinly across 34 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $2,807 and has fallen 65.9% since, to $956 in 2025.
Across 256 payments — averaging $26.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Procept Biorobotics Corporation$1K
- AbbVie$1K
- Bluewind Medical$789
- Astellas Pharma US Inc$566
- Bayer$433
- Johnson & Johnson$414
- plus $2K from 28 others
Across 8 payments — averaging $3089.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- OPKO Pharmaceuticals, LLC$14K
- GSK$11K
What the payments were for
- Travel & lodging$1,36520%
- Food & beverage$5,17077%
- Education$1843%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Procept Biorobotics Corporation | 10 | $1,310 |
| AbbVie(2 entities) | 70 | $1,120 |
| Bluewind Medical | 7 | $789 |
| Astellas Pharma US Inc | 25 | $566 |
| Bayer | 23 | $433 |
| Johnson & Johnson(2 entities) | 19 | $414 |
| Intuitive Surgical | 7 | $231 |
| Endo Pharmaceuticals Inc. | 15 | $230 |
| Antares Pharma, Inc. | 12 | $228 |
| Healthtronics Stone Solutions, LLC | 2 | $201 |
| Axonics, Inc. | 5 | $177 |
| Pfizer | 10 | $167 |
| Coloplast | 6 | $95 |
| Dendreon Pharmaceuticals LLC | 3 | $81 |
| Endo USA, Inc. | 4 | $67 |
| Progenics Pharmaceuticals, Inc. | 3 | $59 |
| Boston Scientific | 3 | $58 |
| Halozyme Inc | 2 | $51 |
| Urovant Sciences Inc | 3 | $49 |
| 180 Medical, Inc. | 2 | $43 |
| Myovant Sciences Inc. | 3 | $40 |
| Tolmar Pharmaceuticals, Inc. | 2 | $39 |
| Urogen Pharma, Inc. | 2 | $37 |
| Sumitomo Pharma America, Inc. | 2 | $35 |
| Immunitybio, Inc. | 1 | $32 |
| Conmed Corporation | 1 | $26 |
| Travere Therapeutics, Inc. | 7 | $23 |
| Myriad Genetic Laboratories, Inc. | 1 | $22 |
| Neotract Inc. | 1 | $22 |
| Laborie Medical Technologies Corp. | 1 | $21 |
| Medtronic | 1 | $16 |
| Verity Pharmaceuticals Inc. | 1 | $14 |
| Smith+Nephew | 1 | $14 |
| Clovis Oncology, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AQUABEAM SYSTEM$1,076
- REVI$718
- Dornier MedTech$499
- CVAC Aspiration System$125
How this compares
$6,720 in reported general payments places this provider in the 70th percentile of 179 urology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 54 | $780,260 |
| NubeqaDarolutamide | 15 | $205,680 |
| OrgovyxRelugolix | 37 | $99,989 |
| GemtesaVibegron | 139 | $99,877 |
| MyrbetriqMirabegron | 93 | $81,220 |
| Testosterone Cypionate | 218 | $10,875 |
| Tamsulosin Hcl | 540 | $9,042 |
| Tolterodine Tartrate ErTolterodine Tartrate | 21 | $6,099 |
| Testosterone | 20 | $4,856 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 99 | $3,670 |
| Finasteride | 181 | $3,283 |
| Tadalafil | 12 | $2,569 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 82 | $2,117 |
| Dutasteride | 57 | $1,612 |
| Potassium Citrate ErPotassium Citrate | 17 | $1,559 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $566 | $861,480147 claims |
| BayerNubeqa | $433 | $205,68015 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $35 | $199,866176 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 179 urology providers in Alabama.
Other urology in Anniston
- Thomas ChiBirmingham$463K
- Joel FunkBirmingham$347K
- Adam BaumgartenBirmingham$271K
- Brian ChristineHomewood$215K
- Vincent BivinsHomewood$117K
- Kyle WoodBirmingham$91K
- Christopher KeelFairhope$68K
- Rachel EngelbergHomewood$61K
- Jeffrey NixBirmingham$54K
- Tracey WilsonBirmingham$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.